admin
Forest Park Pharmacy in Fort Worth blew the whistle this week after a routine refill transfer turned into a clown show. A generic antibiotic the shop buys for about $18 showed up in the insurer’s system as a roughly $2,500 line item, and the plan slapped a prior authorization on the last 14 tablets while the child was mid‑treatment. That viral post from co‑owner Brad Hart is not a one‑off glitch. It exposes how pricing benchmarks and PBM rules can turn everyday medicine into paper money theater.
How a cheap drug becomes a headline — the linezolid story
The drug was linezolid, a generic antibiotic. The pharmacy paid about $18 for the supply. The insurer’s claim adjudication, though, relied on an AWP‑derived price that ballooned the charge into the thousands. When the plan’s system “flagged” that inflated line item, it demanded a prior authorization before the pharmacy could finish the transfer. In plain English: the insurance company invented a cost problem out of a list price, then billed everyone for fixing it.
AWP, PBMs and the paper price problem
AWP — Average Wholesale Price — is a published list number. It was never meant to reflect what real pharmacies pay. PBMs, the middlemen called pharmacy benefit managers, often use AWP or other list numbers in their contracts and adjudication logic. That mismatch lets a harmless generic look like a luxury item on paper. CMS’s NADAC benchmark, which tracks actual pharmacy invoice prices, shows a very different — and far lower — reality. Yet AWP still sits inside thousands of contracts and computer rules that control who gets meds and when.
Why this matters: delays, higher costs, and more fraud
When adjudication runs off list prices, patients lose. Prior authorizations can delay treatment. Pharmacies eat administrative headaches. Taxpayers pay higher claims when public programs rely on warped benchmarks. And big piles of government money naturally attract cheats and skimmers. Recent multimillion‑dollar Medicare fraud cases and long‑running investigations into PBM practices prove the incentives are broken. We shouldn’t act surprised the system is messy when Congress has dumped trillions into health programs and created middlemen with little transparency.
Simple fixes that politicians love to dodge
There are obvious changes that wouldn’t break anything except middlemen profits. Require PBM transparency and stop spread pricing. Move reimbursement to NADAC or other acquisition‑based benchmarks. Make prior authorizations faster and more accountable. And stop forcing folks into opaque third‑party schemes so they can’t shop for cash prices that actually reflect market reality. Independent pharmacies like Forest Park already show one sane path: sell at fair market markups, not whatever AWP tells a computer to pretend.
Brad Hart’s post was short and sharp because the problem is simple and dumb. The antidote is not more committees or slogans about “affordability.” It’s cutting the paper games out of the system, letting real prices matter, and forcing transparency on the players who profit from complexity. Until lawmakers do that, an $18 antibiotic will keep showing up as a $2,500 mystery — and patients will keep paying in time, money, and health.
